MedWatch

Novozymes in collaboration with US biotech company

A new collaboration agreement with a US biotech outfit is going to secure a broader technology platform for Novozymes’ biopharma-division.

Foto: Novozymes/PR

Late last week the Danish company Novozymes signed a partnership deal with the biotech company EpiVax.

The US company is currently developing a technology platform called Tregitopes, which is aimed at treating autoimmune diseases, such as type 1 diabetes, lupus, psoriasis and multiple sclerosis.

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier